# Quantum BioPharma Narrows Q3 Loss; Continuing-Operations Loss Per Share Is $0.06

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/56957
Published: 2026-11-13T18:32:47.000Z
Updated: 2026-11-13T18:32:47.000Z
Section: Business

> Digital-asset holdings rose to $8.66 million at Sept. 30, while a calculation using the loss attributable to equity owners implies about $0.04 per share.

Quantum BioPharma Ltd. narrowed its third-quarter net loss to $474,279 from $4,747,600 a year earlier, while basic and diluted loss per share from continuing operations was $0.06 for the quarter ended Sept. 30.

The per-share loss was $1.25 in the year-earlier quarter. A separate calculation using the $297,088 net loss attributable to equity owners and 7,981,356 weighted-average shares implies a loss of about $0.04 per share. Quantum BioPharma did not explain the difference between that calculation and the reported $0.06 figure.

Third-quarter operating expenses declined to $3,555,060 from $4,678,127. The company recorded a $2,795,502 unrealized gain on digital assets and a $230,541 realized gain on digital-asset sales.

Digital-asset holdings were valued at $8,658,775 on Sept. 30, up from $3,815,440 on Dec. 31, 2025. The balance was unrestricted after Quantum BioPharma repaid its BitGo loan during the period. Its holdings included Bitcoin (BTC), Solana (SOL), Ether (ETH), XRP, SUI and LINK.

For the first nine months of 2026, the company’s net loss was $17,320,779, compared with $23,253,808 in the same period of 2025. Operating activities used $6,254,840 in cash during the nine-month period. Quantum BioPharma focuses on drug candidates for disorders including multiple sclerosis and alcohol misuse.